Common side effects(may affect up to 1 in 10 people):
Uncommon side effects(may affect up to 1 in 100 people):
Rare side effects(may affect up to 1 in 1,000 people):
Very rare side effects(may affect up to 1 in 10,000 people):
Side effects not known(the frequency cannot be estimated from available data):
The class of medicines to which Quetiapine Kern Pharma belongs may cause serious heart rhythm problems that can be life-threatening.
Some side effects are only seen when a blood test is done. These include changes in the amount of certain fats (triglycerides and total cholesterol) or sugar in the blood, changes in the amount of thyroid hormones in the blood, increased liver enzymes, decreases in the number of certain types of blood cells, decreases in the number of red blood cells, increased creatine phosphokinase in the blood (a substance found in muscles), decreases in the amount of sodium in the blood, and increases in the amount of prolactin hormone in the blood. Increases in prolactin hormone may, in rare cases, lead to the following:
Your doctor may ask you to have blood tests from time to time.
Side effects in children and adolescents
The same side effects that may occur in adults may also occur in children and adolescents.
The following side effects have been observed more frequently in children and adolescents or have not been observed in adults:
Very common side effects(may affect more than 1 in 10 people):
-Girls may not have a menstrual period or have irregular periods.
Common side effects(may affect up to 1 in 10 people):
Reporting side effects
If you experience any type of side effect, consult your doctor, pharmacist, or nurse, even if it is a possible side effect that does not appear in this leaflet. You can also report them directly through the Spanish System for Pharmacovigilance of Medicines for Human Use:www.notificaram.es. By reporting side effects, you can contribute to providing more information on the safety of this medicine.
Keep this medication out of the sight and reach of children.
Do not use this medication after the expiration date that appears on the packaging after CAD. The expiration date is the last day of the month indicated.
Quetiapina Kern Pharma does not require special conditions for conservation.
Medicines should not be thrown down the drains or in the trash. Dispose of the packaging and medicines you no longer need at the SIGRE collection point of the pharmacy. If in doubt, ask your pharmacist how to dispose of the packaging and medicines you no longer need. By doing so, you will help protect the environment.
Composition of Quetiapina Kern Pharma
The active ingredient is quetiapine. The tablets contain 50 mg of quetiapine (as quetiapine hemifumarate).
The other components are:
Tablet core: lactose monohydrate, hypromellose, sodium chloride, povidone K-30, microcrystalline cellulose silicified (silica dioxide and microcrystalline cellulose), talc, and magnesium stearate (E572).
Tablet coating: polyvinyl alcohol, titanium dioxide (E171), macrogol (E553b), talc, iron oxide red (E172), and iron oxide yellow (E172).
Appearance of Quetiapina Kern Pharma and content of the packaging
The tablets are orange-colored, round, biconvex, film-coated, and engraved with the inscription “Q50” on one face and smooth on the other face. They are presented in PVC/PVDC/Aluminum blisters or in Alu/Alu blisters, in packs of 10 or 60 tablets.
Only some pack sizes may be commercially available.
Holder of the marketing authorization
Kern Pharma, S.L.
Venus, 72 - Pol. Ind. Colón II
08228 Terrassa – Barcelona
Spain
Responsible for manufacturing
Kern Pharma, S.L.
Venus, 72 - Pol. Ind. Colón II
08228 Terrassa - Barcelona
Spain
Last review date of this leaflet:June 2024
The detailed and updated information on this medication is available on the website of the Spanish Agency for Medicines and Medical Devices (AEMPS) http://www.aemps.gob.es/
Есть вопросы по этому лекарству или вашим симптомам? Свяжитесь с лицензированным врачом для получения помощи и персонализированного ухода.